SCHEMBL4450229

SCHEMBL4450229

O=C(O)CCCC1CCC([Sn]c2nc(Nc3ccc(Cl)cc3)ncc2[N+](=O)[O-])CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 1/20 0.45
GSK3B P49841 7/20 0.43
GSK3A P49840 6/20 0.43
PRKCQ Q04759 7/20 0.42
AURKA O14965 3/20 0.41
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
PTK2B Q14289 1/20 0.39
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
SYK P43405 1/20 0.36
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1916927 0.83 STK17A (0.52) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL1917005 0.78 GSK3B (0.52) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL1918925 0.78 PRKCQ (0.61) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL1916414 0.76 STK17A (0.45) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL3290941 0.74 STK17A (0.76) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL3286605 0.73 STK17A (0.74) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL1916987 0.73 STK17A (0.52) STK17AGSK3BGSK3APRKCQAURKA
SCHEMBL1917655 0.72 STK17A (0.73) STK17AGSK3BGSK3APRKCQAURKA
Hexanoate SCHEMBL3283574 0.72 STK17A (0.52) STK17AGSK3BGSK3AAURKAMAPT
SCHEMBL1918297 0.72 STK17A (0.72) STK17AGSK3BGSK3APRKCQAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2090571-A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2009-08-19 EP disclosed